Solventum (SOLV)

NYSE Health Care Health Care Technology S&P 500
$90.38
+3.20 (+3.67%)
Close of Nov 06, 2026 · end-of-day data

SOLV 8-K filings in 2024

Every material Form 8-K Solventum filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.

Briefs in 2024116 on record in all
Latest filing in 2024Nov 07, 2024earnings
High impact (4-5)1of 1 brief
ToneMixed1
Nov 7, 4:14 PM ET

Solventum raises 2024 guidance as Q3 sales edge up 0.4% and GAAP EPS falls to $0.70

Mixed earnings Written later 2.02

Solventum reported third-quarter 2024 sales of $2.082 billion, up 0.4%, while GAAP earnings per share fell to $0.70 from $2.66 a year earlier and adjusted EPS was $1.64 versus $2.87. The company raised its full-year 2024 adjusted EPS guidance to $6.50 to $6.65 from $6.30 to $6.50, so shareholders get a higher outlook alongside a sharp drop in quarterly profit.

  • Q3 2024 net sales $2.082 billion, up 0.4%; organic sales up 0.3%
  • GAAP EPS $0.70 vs. $2.66 in Q3 2023; adjusted EPS $1.64 vs. $2.87
  • Full-year 2024 adjusted EPS guidance raised to $6.50 to $6.65 (previously $6.30 to $6.50)
  • Full-year free cash flow guidance raised to $750 million to $850 million (previously $700 million to $800 million)
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Solventum filing is on SEC EDGAR ↗. 8-K briefs of other companies →